- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | MiNK Therapeutics Announces Virtual Annual Shareholders Meeting | 1 | GlobeNewswire (USA) | ||
| 02.06. | MiNK Therapeutics receives NIH grant for GvHD therapy | 2 | Investing.com | ||
| 02.06. | MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients | 2 | GlobeNewswire (USA) | ||
| 15.05. | MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programs | 2 | Seeking Alpha | ||
| 15.05. | MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress | 169 | GlobeNewswire (Europe) | Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1-resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK... ► Artikel lesen | |
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | MiNK Therapeutics GAAP EPS of -$0.70 misses by $0.09 | 1 | Seeking Alpha | ||
| 15.05. | MiNK Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 05.05. | MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report | 2 | GlobeNewswire (USA) | ||
| 18.03. | MiNK Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | MiNK Therapeutics, Inc. Q4 Loss Decreases, But Misses Estimates | - | RTTNews | ||
| 18.03. | MiNK Therapeutics GAAP EPS of -$0.62 misses by $0.12 | - | Seeking Alpha | ||
| 18.03. | MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress | 213 | GlobeNewswire (Europe) | NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural... ► Artikel lesen | |
| 18.03. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.02. | MiNK Therapeutics stock target soars to $35 at H.C. Wainwright | 2 | Investing.com | ||
| 24.02. | MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting | 186 | GlobeNewswire (Europe) | NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural... ► Artikel lesen | |
| 20.02. | MiNK Therapeutics regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 20.02. | MiNK Therapeutics erfüllt wieder Nasdaq-Anforderungen | 1 | Investing.com Deutsch | ||
| 20.02. | MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements | 177 | GlobeNewswire (Europe) | NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic... ► Artikel lesen | |
| 12.02. | MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,450 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| SILEXION THERAPEUTICS | 0,800 | 0,00 % | Silexion Therapeutics Corp: Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers | GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 5,010 | 0,00 % | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | ||
| VOR BIOPHARMA | 0,890 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 40,330 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,255 | 0,00 % | BMO Capital stuft Verve Therapeutics nach Eli Lilly-Übernahme herab | ||
| RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| QIAGEN | 41,035 | -0,47 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,380 | 0,00 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| KYMERA THERAPEUTICS | 45,720 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,020 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations | - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 9,550 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| KEROS THERAPEUTICS | 13,510 | 0,00 % | Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders | LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen |
MINK THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 7,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.